UNSPSC 51171974: Imiglucerase

This classification denotes an enzyme replacement preparation with the molecular formula C2532H3843N671O711S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q6U6J48BWY, more generally known as imiglucerase. European Medicines Agency schedules imiglucerase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08148MIG. The term IMIGLUCERASE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 9, no. 3, 1995, list 35.

UNSPSC 51171974 Imiglucerase is a Commodity code that describes a specific glucosidase-inhibitor enzyme replacement therapy for Gaucher disease; however, recent state and local procurement activity shows no direct solicitations for imiglucerase itself. The three opportunities posted under this code between January and July 2026 concern drug testing services (specimen collection and immunoassay screening), a Therapeutic Pharmacy Initiative market-intelligence request from the Texas Health and Human Services Commission, and a multistate cooperative pharmaceutical-supply agreement from the Minnesota Multistate Cooperative Purchasing Alliance. These solicitations address pharmacy benefit administration, drug screening logistics, and generic pharmaceutical distribution rather than enzyme replacement therapies. The issuing bodies include county corrections departments (Collin County, Texas), state health agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (MMCAP).

Geographic activity concentrates in Texas and Minnesota with Oregon participation through MMCAP. The Collin County Community Supervision and Corrections Department issued an RFP (2026-327) due July 23, 2026, for offender specimen collection and drug testing services with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026; the Minnesota Department of Administration issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products through MMCAP, with contract effectiveness July 1, 2026. The Texas HHS Commission posted an RFI (HHS0017013) in March 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs without a formal response deadline or award timeline. The code shows limited procurement relevance to its nominal product scope; vendors pursuing state and local specialty-pharmaceutical contracts should monitor broader pharmacy benefit and drug-distribution categories rather than rely on imiglucerase-specific solicitations.